|
| ENT* | Digestive | Respiratory | MS | GU |
| Target lesions |
|
|
|
|
|
| Baseline | 1 | 15 | 3 | 4 | 51 |
| 1st assessment | 1 | 12 | 3 | 2 | 42 |
| 2nd assessment | 1 | 11 | 0 | 0 | 41 |
| Non-target lesions |
|
|
|
|
|
| Baseline | 0 | 4 | 2 | 0 | 30 |
| 1st assessment | 0 | 3 | 1 | 0 | 22 |
| 2nd assessment | 0 | 6 | 1 | 0 | 14 |
| New lesions |
|
|
|
|
|
| 1st assessment | 0 | 1 | 1 | 0 | 9 |
| 2nd assessment | 0 | 12 | 1 | 0 | 16 |